Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Levetiracetam 1000 mg Under Fasting Conditions

NCT00859521
Conditions
Healthy
Interventions
Levetiracetam, Keppra®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Healthy
Interventions
Levetiracetam
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Neptune City, New Jersey
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacologic Modulation of Hippocampal Activity in Psychosis

NCT04277936
Conditions
Schizophrenia; Psychosis
Interventions
Levetiracetam 500 mg
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Nashville, Tennessee
Completed No phase listed Observational Accepts healthy volunteers Results available

Premenstrual Dysphoric Disorder and Antiepileptic Drugs

NCT00612235
Conditions
Epilepsy
Interventions
Lamotrigine, Levetiracetam, Carbamazepine, No Intervention
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts • Newton, Massachusetts
Completed Phase 4 Interventional Results available

Seizure Prophylaxis in Aneurysm Repair

NCT01801072
Conditions
Intracranial Aneurysms, Seizure
Interventions
Levetiracetam
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Alzheimer's Disease
Interventions
levetiracetam
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Conditions
Splenomegaly, Myelofibrosis
Interventions
Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam, Eltrombopag, Busulfan, Romiplostim, Fludarabine phosphate, Cyclophosphamide, Mesna, Tacrolimus
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 4 Interventional Accepts healthy volunteers

The Effects of Levetiracetam on Alcohol Dependent Subjects

NCT00325182
Conditions
Alcoholism
Interventions
Levetiracetam, Historical controls
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy Volunteers
Interventions
[11C]UCB-J, Brivaracetam, Levetiracetam
Radiation · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
60 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1Phase 2 Interventional Results available

Efficacy of Intravenous Levetiracetam in Neonatal Seizures

NCT01720667
Conditions
Neonatal Seizures
Interventions
Intravenous levetiracetam, Intravenous phenobarbital
Drug
Lead sponsor
Richard H. Haas
Other
Eligibility
15 Minutes to 14 Days
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Diego, California
Conditions
Obsessive-Compulsive Disorder
Interventions
Sertraline, Levetiracetam, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Interventions
Levetiracetam
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Parkinson's Disease
Interventions
levetiracetam, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
30 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Dyskinesias, Parkinson Disease
Interventions
Intravenous Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cocaine Dependence, Opioid Dependency
Interventions
levetiracetam, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Tonic-clonic Seizure
Interventions
Keppra, Fosphenytoin, Dilantin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 1Phase 2 Interventional Results available

Dosing of Levetiracetam (Keppra) in Neonates

NCT01239212
Conditions
Seizures
Interventions
levetiracetam
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 30 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Alcoholism, Alcohol Dependence, Alcohol Abuse
Interventions
Topiramate, Zonisamide, Levetiracetam, Sugar Pill
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy, Myoclonic Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
Interventions
Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells, Thymoglobulin, Cyclophosphamide
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Epilepsy
Interventions
Levetiracetam (Keppra)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
65 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

NCT03034356
Conditions
Schizophrenia
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado